A similar result was obtained in the HERALD study of patritumab, another ErbB3-targeted monoclonal antibody developed by Daiichi Sankyo.52 In this Phase 1b/2 study, patritumab in combination with erlotinib was compared with patritumab plus placebo in EGFR inhibitor-naïve advanced NSCLC. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.